Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines

Vaccine

Volumn 27, Issue 32, 2009, Pages 4337-4349

  McBurney, Sean P ^a   Ross, Ted M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Consensus; HIV 1 vaccine; Polyvalent; Virus like particles

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOVALENT ENV VACCINE; POLYVALENT ENV VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD; CELLULAR IMMUNITY; CLADISTICS; CONSENSUS; CONTROLLED STUDY; DRUG DESIGN; ENVELOPE GENE; FEMALE; GENETIC DIFFERENCE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOREACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; RNA SEQUENCE; VIRUS ISOLATION; VIRUS LIKE AGENT; VIRUS STRAIN;

ADMINISTRATION, INHALATION; AIDS VACCINES; ANIMALS; CONSENSUS SEQUENCE; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; VACCINES, VIROSOME;

EID: 67649472415     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.032     Document Type: Article

References (70)

1. Robertson D.L., Anderson J.P., Bradac J.A., et al. A Reference Guide to HIV-1 Classification. In: Kuiken C.L., Foley B., Hanh B.H., et al. (Eds). Human retroviruses and AIDS: A Compilation and Analysis of Nucleic and Amino Acid Sequences (2000), Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 492-505
2. Thomson M.M., Perez-Alvarez L., and Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2 8 (2002) 461
3. Berman P.W., Gregory T.J., Riddle L., Nakamura G.R., Champe M.A., Porter J.P., et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345 6276 (1990) 622-625
4. Cho M.W., Kim Y.B., Lee M.K., Gupta K.C., Ross W., Plishka R., et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 75 March (5) (2001) 2224-2234
5. Johnston M.I., and Flores J. Progress in HIV vaccine development. Curr Opin Pharmacol 1 5 (2001) 504-510
6. Polacino P., Stallard V., Klaniecki J.E., Montefiori D.C., Langlois A.J., Richardson B.A., et al. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol 73 January (1) (1999) 618-630
7. Azizi A., Anderson D., Ghorbani M., Gee K., and Diaz-Mitoma F. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters. BMC Immunol 7 1 (2006) 25
8. Chakrabarti B.K., Ling X., Yang Z.-Y., Montefiori D.C., Panet A., Kong W.-P., et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 23 26 (2005) 3434
9. Ljungberg K., Rollman E., Eriksson L., Hinkula J., and Wahren B. Enhanced Immune Responses After DNA Vaccination with Combined Envelope Genes from Different HIV-1 Subtypes. Virology 302 1 (2002) 44
10. Rollman E.J.H., Arteaga J., Zuber B., Kjerrstrom A., Liu M., Wahren B., et al. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther 11 July (14) (2004) 1146-1154
11. Wang S., Pal R., Mascola J.R., Chou T-HW, Mboudjeka I., Shen S., et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350 1 (2006) 34-47
12. Slobod K., Coleclough C., Bonsignori M., Brown S.A., Zhan X., Surman S., et al. HIV vaccine rationale, design and testing. Curr HIV Res 3 April (2) (2005) 107-112
13. Kong W.-P., Huang Y., Yang Z.-Y., Chakrabarti B.K., Moodie Z., and Nabel G.J. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77 December (23) (2003) 12764-12772
14. Denys L.F.B., Lebigot S., Verrier B., Buzelay L., Brunet S., and Barin F. Immunogenicity of recombinant envelope glycoproteins derived from T-Cell line-adapted isolates or primary HIV isolates: a comparative study using multivalent vaccine approaches. JAIDS J Acquir Immune Defic Syndr 26 April (5) (2001) 413-422
15. Pal R., Wang S., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 34 5-6 (2005) 226-236
16. Pal R., Wang S., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348 May (2) (2006) 341-353
17. Seaman M.S., Xu L., Beaudry K., Martin K.L., Beddall M.H., Miura A., et al. Multiclade human immunodeficiency virus Type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79 March (5) (2005) 2956-2963
18. Slobod K.S., Lockey T.D., Howlett N., Srinivas R.V., Rencher S.D., Freiden P.J., et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 23 2 (2004) 106
19. Lu S. Immunogenicity of Monovalent and Polyvalent Dna Prime/Protein Boost Formulation Encoding Primary Hiv-1 Env Antigens as Tested in Rabbits and Non-Human Primate Models (2004), Keystone Symposia, Keystone, CO
20. McBurney S.P., and Ross T.M. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines. Curr Pharm Des 13 (2007) 1957-1964
21. Feng Gao H.-X., Hahn B.H., Letvin N.L., Korber BetteT., and Haynes B.F. Centralized HIV-1 envelope immunogens and neutralizing antibodies. Curr HIV Res 5 November (6) (2007) 572-577
22. Gao F. Consensus and ancestral state of HIV vaccines. Science 299 (2003) 1515-1518
23. Gao F., Weaer E.A., and Lu Z. Antigenicity and Immunogenicity of a synthetic HIV-1 Group M consensus envelope glycoprotein. Virology 360 March (1) (2007) 218-234
24. Kulken C. HIV-1 consensus sequences. HIV-1 Sequence Compendium (2002)
25. Nyambi P. Multivariate analysis of HIV-1 neutralization data. J Virol 70 (1996) 6235-6243
26. Parren P.W. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of eptiope specificity. J Virol 73 (1998) 3512-3519
27. Gaschen B. DIversity considerations in HIV-1 vaccine selection. Science 296 (2002) 2354-2360
28. Korber B.T., Brander C., and Haynes B. HIV Molecular Immunology 2002 (2002), Theoretical Biology and Biophysics Group:Los Alamos National Laboratory
29. Zhan X. Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells. Vaccine 22 (2004) 1206-1213
30. Yusim K., Kesmir C., and Gaschen B. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 76 (2002) 8757-8768
31. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4 (2004) 199-210
32. Gao F., Weaver E.A., Lu Z., Li Y., Liao H.-X., Ma B., et al. Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein. J Virol 79 January (2) (2005) 1154-1163
33. Doria-Rose N.A., Learn G.H., Rodrigo A.G., Nickle D.C., Li F., Mahalanabis M., et al. Human immunodeficiency virus type 1 subtype b ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 79 September (17) (2005) 11214-11224
34. Green T.D., Montefiori D.C., and Ross T.M. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 77 3 (2003) 2046-2055 Feb
35. Young K.R., Smith J.M., and Ross T.M. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle. Virology 327 2 (2004) 262-272
36. Lowe D.M., Parmar V., Kemp S.D., and Larder B.A. Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase. FEBS Lett 282 May (2) (1991) 231-234
37. Mizuno A., Ido E., Goto T., Kuwata T., Nakai M., and Hayami M. Mutational analysis of two zinc finger motifs in HIV type 1 nucleocapsid proteins: effects on proteolytic processing of Gag precursors and particle formation. AIDS Res Hum Retroviruses 12 June (9) (1996) 793-800
38. Chao S.F., Chan V.L., Juranka P., Kaplan A.H., Swanstrom R., and Hutchison III C.A. Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res 23 March (5) (1995) 803-810
39. Le Grice S.F., Naas T., Wohlgensinger B., and Schatz O. Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. Embo J 10 December (12) (1991) 3905-3911
40. Tilney N.L. Patterns of lymphatic drainage in the adult laboratory rat. J Anat 109 (1971) 369-383
41. Huang Y., Kong W.P., and Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 75 May (10) (2001) 4947-4951
42. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., and Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 166 Mar (5) (2001) 3451-3457
43. Kang S.M., and Compans R.W. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol 77 March (6) (2003) 3615-3623
44. Horner A.A., Ronaghy A., Cheng P.M., Nguyen M.D., Cho H.J., Broide D., et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 190 November (1) (1998) 77-82
45. McCluskie M.J., and Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 161 November (9) (1998) 4463-4466
46. Moldoveanu Z., Vzorov A.N., Huang W.Q., Mestecky J., and Compans R.W. Induction of immune responses to SIV antigens by mucosally administered vaccines. AIDS Res Hum Retroviruses 15 November (16) (1999) 1469-1476
47. Bower J.F., Yang X., Sodroski J., and Ross T.M. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 78 (2004) 4710-4719
48. Bower J.F., Sanders K.L., and Ross T.M. C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences. Curr HIV Res 3 April (2) (2005) 191-198
49. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV and SHIV in a luciferase reporter gene assay. In: Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W., and Coico R. (Eds). Current Protocols in Immunology (2004), John Wiley & Sons
50. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 August (16) (2005) 10108-10125
51. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., et al. Genetic and neutralization properties of subtype c human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80 December (23) (2006) 11776-11790
52. Roederer M., and Koup R.A. Optimized determination of T cell epitope responses. J Immunol Methods 274 1-2 (2003) 221-228
53. McBurney S.P., Young K.R., and Ross T.M. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 358 2 (2007) 334-346
54. Crooks E.T., Moore P.L., Franti M., Cayanan C.S., Zhu P., Jiang P., et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366 2 (2007) 245-262
55. UNAIDS. AIDS epidemic update: December 2006: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2006 (December).
56. Brandtzaeg P.B.E.S., Farstad I.N., Jahnsen F., et al. Regional specialization in the mucosal immune systen: what happens in the microcompartments?. Immunology Today 20 (1999) 141-151
57. Kaneko H.B.I., Wierzbicki A., et al. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 267 (2000) 8-16
58. McGhee J.R.M. J. In defense of mucosal surfaces: development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect Dis Clin N Am 4 (1990) 315-341
59. Tochikubo K., Isaka M., Yasuda Y., Kozuka S., Matano K., Miura Y., et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine 16 2-3 (1998) 150-155
60. Verthelyi D., Wang V.W., Lifson J.D., and Klinman D.M. CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS 18 (2004) 1003-1008
61. Verthelyi D., Kenney R.T., Seder R.A., Gam A.A., Friedag B., and Klinman D.M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 168 February (4) (2002) 1659-1663
62. Verthelyi D., and Klinman D.M. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 109 October (1) (2003) 64-71
63. Leifer C.A., Verthelyi D., and Klinman D.M. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J Immunother 26 (2003) 313-319
64. McBurney S.P., Young K.R., and Ross T.M. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 358 February (2) (2007) 334-346
65. Yao Q., Vuong V., Li M., and Compans R.W. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 20 June (19-20) (2002) 2537-2545
66. Wu H.Y., Nguyen H.H., and Russell M.W. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand J Immunol 46 5 (1997) 506-513
67. Sminia TD G. Nasal-associated lymphoid tissue. In: ra PLL E., enenstock J., estecky J., Stober W., and McGhee J.R. (Eds). Mucosal Immunology (1999), Academic Press, London 357-364.
68. Johansson E.-L., Wassen L., Holmgren J., Jertborn M., and Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 69 December (12) (2001) 7481-7486
69. Kozlowski P.A., Cu-Uvin S., Neutra M.R., and Flanigan T.P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 65 April (4) (1997) 1387-1394
70. Nardelli-Haefliger D., Wirthner D., Schiller J.T., Lowy D.R., Hildesheim A., Ponci F., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95 August (15) (2003) 1128-1137